about
Miliary pattern on chest radiography: TB or not TB?Novel agents for advanced pancreatic cancerSTAT inhibitors for cancer therapy.APACHE II scores as predictors of cardio pulmonary resuscitation outcome: Evidence from a tertiary care institute in a low-income country.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Ibrutinib and indolent B-cell lymphomas.Germline mutations predisposing to non-small cell lung cancer.Novel ALK inhibitors in clinical use and development.O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.SBRT to adrenal metastases provides high local control with minimal toxicity.Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy.Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.The Conundrum of "Warfarin Hypersensitivity": Prolonged Partial Thromboplastin Time From Factor IX Propeptide Mutation.O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateComparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).Air leakage in multiple compartments after endoscopyAtezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials
P50
Q24655609-CD784060-110F-4DBA-99CE-E5807D6669E9Q26787087-24B9A6B9-1662-4473-9EAD-FB240E4C83ACQ33644206-D9CBEF08-5C45-46C9-ACCE-9A55877644EBQ35820812-0F18B6FF-8954-4500-B908-F21975CCF038Q37350230-6B943529-C2AC-4D61-ADE7-1FEF14126FEEQ38180278-6828E056-3123-429A-A306-D654D00F56BFQ38392359-94D8BD5F-17CB-47DC-93AB-FDB7559FFBFEQ38427240-150154D2-E48E-4047-ACCD-69C0A0533179Q38709364-B45CD690-06D0-43BC-AB14-769B526B5E1BQ47275101-77EF4DD0-D2F8-45F4-A416-6D8EEA402532Q51815957-904F04E1-EC23-4A7A-B439-81E8DE12B08AQ53062630-97441E07-E017-43CA-BF0B-968275ECC85FQ53089934-44055EED-F0C4-4CE5-B17F-1DB01FCE1A72Q57598558-68CF048A-957F-4D86-B314-6E7A743B6F44Q64906919-B64241C7-A857-48DE-B86A-2D8FAA2942AEQ88528902-7DCFD794-0E95-43E9-8826-BA01A5CEAB23Q88791416-B2BE2DEC-A685-46E7-AD45-58F340A58B27Q91335558-F8FC19FF-8914-4D64-9177-6F89C8F970D1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Muhammad Furqan
@en
Muhammad Furqan
@nl
type
label
Muhammad Furqan
@en
Muhammad Furqan
@nl
prefLabel
Muhammad Furqan
@en
Muhammad Furqan
@nl
P31
P496
0000-0003-3137-2053